BioSpecifics Technology provides corporate update tadora 20 mg reviews.

BioSpecifics Technology provides corporate update, reports Q4 and FY 2014 financial outcomes BioSpecifics Technology Corp tadora 20 mg reviews .S. ‘Recently is a year of incredible development commercially for XIAFLEX. In the U.S., we saw a substantial upsurge in total XIAFLEX revenues in 2014, powered by the launch in Peyronie's disease. This boost was obvious in the royalties and mark-up on COGS revenues in 2014, which a lot more than doubled when compared to previous calendar year. Revenues exceeded goals and we are wanting to see rising product sales of XIAFLEX for sufferers in the U.S.